Multiple insiders have executed 6 significant purchases totaling over $421,000 in the past month, demonstrating remarkable confidence in $TriSalus Life Sciences (TLSI.US)$. This insider accumulation comes alongside impressive Q4 results showing 44% YoY revenue growth to $8.3M and full-year 2024 revenue up 59% to $29.4M.  🚀Worth watching this emerging player in the $4.56B cancer therapeutics market! Read our complete analysis: TriSalus Life Sciences Because Its Approach to Cancer Therapy Stands Out | Investment Review
...

$RenovoRx (RNXT.US)$
Revolutionary Cancer Drug Delivery System: RenovoRx's TAMP Platform Shows Breakthrough Results

$RenovoRx (RNXT.US)$
RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025
Monday, 27th January at 8:00 am
Abstract was presented by TIGeR-PaC Phase III clinical trial Investigator, Paula Novelli, MD, from the University of Pittsburgh Medical Center
Sub-study of the pivotal Phase III TIGeR-PaC clinical trial offers insight that supports the potential effectiveness of RenovoRx's TAMP therapy platform in locally advanced pancreatic cancer
PK data shows intra-a...

$RenovoRx (RNXT.US)$
RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer
11 minutes ago, 5:00 AM PST
Via GlobeNewswire
RNXT
Share
TIGeR-PaC is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer
Dr. Meredith Pelster, Associate Director for GI Research Across Sarah Cannon Research Institute (SCRI), Appointed Princi...

$RenovoRx (RNXT.US)$
RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System
Thursday, 5th December at 8:00 am
Over Ten Medical Institutions Nationwide have Initiated RenovoCath Purchase Process, Further Accelerating Commercialization Strategy
RenovoRx Estimates Initial Target Market Size for RenovoCath of Several Hundred Million Dollars in Annual Sales
Global Medical Device Commercial Leader, Richard Stark, Joining RNXT as Commercial Advisor
LOS ALTOS, Cal...

$RenovoRx (RNXT.US)$ $Backblaze (BLZE.US)$ $Exact Sciences (EXAS.US)$ $Elevance Health (ELV.US)$
RNXT SMA200 is $1.20, if we can hold above , that's bullish for sure IMO
But always have that protection in place for the profits !
MORE INFO BELOW 👇
https://chartingdaily.com/delivering-therapy-where-it-matters-now
Communicated disclaimer

$RenovoRx (RNXT.US)$ Northwell Health Cancer Institute Launches Patient Enrollment in Renovorx’s Ongoing Pivotal Phase III Tiger-Pac Clinical Trial

$RenovoRx (RNXT.US)$
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
5 minutes ago, 5:45 AM PST
Via GlobeNewswire
The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025
Phase III Clinical Trial is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Loc...

$RenovoRx (RNXT.US)$
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
LOS ALTOS, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Ripal Gandhi, M.D., FSIR, FSVM will present at the...

$RenovoRx (RNXT.US)$
RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
RenovoRx (Nasdaq: RNXT) has announced the enrollment of the first patient at the University of Nebraska Medical Center (UNMC) for its ongoing Phase III TIGeR-PaC clinical trial. The study is evaluating RenovoGem™, a novel therapy for Locally Advanced Pancreatic Cancer (LAPC) using the TAMP™ (Trans-Arterial Micro-Perfusion) platform....